Published in Br J Cancer on January 01, 1993
Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Pathol (1994) 1.50
Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis. Oncol Lett (2013) 0.82
The effects of pentoxifylline on the relative perfusion of tumours growing in three sites in the mouse. Br J Cancer (1993) 0.77
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med (1981) 4.90
Regional blood flow by fractional distribution of indicators. Am J Physiol (1958) 3.72
Chemical modification of tumour blood flow. Int J Hyperthermia (1988) 1.36
Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst (1990) 1.33
Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res (1989) 1.20
Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys (1988) 1.08
Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res (1985) 0.91
Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. Int J Radiat Oncol Biol Phys (1986) 0.86
Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck. Br J Cancer (1989) 0.85
Radiosensitization effects of nicotinamide on malignant and normal mouse tissue. Cancer Res (1985) 0.84
Metoclopramide enhances the effect of ionizing radiation on xenografted squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (1990) 0.81
The benzamide derivative metoclopramide causes DNA damage and inhibition of DNA repair in human peripheral mononuclear leukocytes at clinically relevant doses. Carcinogenesis (1991) 0.81
Dose schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous cell carcinomas of the head and neck. Anticancer Drugs (1991) 0.80
Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy. Biomed Biochim Acta (1989) 0.79
SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys (1986) 1.87
Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer (1995) 1.16
Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res (1988) 1.11
Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys (1988) 1.08
2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res (1996) 0.97
Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol (1988) 0.93
The influence of vasoactive agents on the perfusion of tumours growing in three sites in the mouse. Int J Radiat Biol (1991) 0.88
Changes in tumour morphology with alterations in oxygen availability: further evidence for oxygen as a limiting substrate. Br J Cancer (1991) 0.87
Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. Cancer Res (1987) 0.84
Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508. Int J Radiat Oncol Biol Phys (1984) 0.83
The effect of vitamin B6 on the neurotoxicity and pharmacology of desmethylmisonidazole and misonidazole: clinical and laboratory studies. Int J Radiat Oncol Biol Phys (1984) 0.82
Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. Cancer Res (1983) 0.81
Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule. Int J Radiat Oncol Biol Phys (1986) 0.80
The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse. Br J Cancer (1993) 0.80
Direct comparison of bromodeoxyuridine and Ki-67 labelling indices in human tumours. Cell Prolif (1996) 0.79
Early detection of damage following bilateral renal irradiation in the mouse. Radiother Oncol (1991) 0.79
Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Int J Radiat Oncol Biol Phys (1996) 0.79
A comparison of radiosensitization by etanidazole and pimonidazole in mouse tumors. Int J Radiat Oncol Biol Phys (1991) 0.76
An even closer look at therapeutic touch. JAMA (1998) 0.75
Radioprotection of normal tissues of the mouse by hypoxic breathing. Int J Radiat Oncol Biol Phys (1989) 0.75
Radiosensitization of mouse skin by oxygen and depletion of glutathione. Int J Radiat Oncol Biol Phys (1995) 0.75
The current status of drug development of hypoxic cell radiosensitizers and their potential role in gynecologic oncology. Gynecol Oncol (1984) 0.75
The effect of BW12C on the radiosensitivity and necrosis of murine tissues and tumours. Australas Radiol (1994) 0.75
Therapeutic touch. Kans Nurse (1988) 0.75
Role of glutathione peroxidase in the radiation response of mouse kidney. Int J Radiat Oncol Biol Phys (1989) 0.75
Is oxygen the limiting substrate for the expansion of cords around blood vessels in tumours? Adv Exp Med Biol (1994) 0.75